Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cenvacibart

An immunoglobulin G4 (igG4), human anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, cenvacibart targets and binds to the catalytic domain of FXI, thereby preventing the activation of FXI (FXIa). The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-factor XI antibody REGN7508
anti-factor XI monoclonal antibody REGN7508
anti-FXI monoclonal antibody REGN7508
Code name:REGN 7508
REGN-7508
REGN7508
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search